The present invention relates to a process for the preparation of erythromysin derivatives, in particular telithromycin of formula (I) and its pharmaceutically acceptable salts, providing the isolated intermediates in crystalline form of superior stability and purity.

The present application describes deuterium-enriched telithromycin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.

The present application describes deuterium-enriched telithromycin pharmaceutically acceptable salt forms thereof and methods of treating using the same.

The present invention relates to stable amorphous 3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribohexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]erythromycin (telithromycin), methods for the preparation thereof, the use of stable amorphous telithromycin in the treatment of bacterial infections and to pharmaceutical compositions comprising stable amorphous telithromycin.

The present invention relates to stable amorphous 3-De[(26-dideoxy-3-C-methyl-3-O-methyl-?-L-ribohexopyranosyl)oxy]-1112-dideoxy-6-O-methyl-3-oxo-1211-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]erythromycin (telithromycin) methods for the preparation thereof the use of stable amorphous telithromycin in the treatment of bacterial infections and to pharmaceutical compositions comprising stable amorphous telithromycin.

Solid pharmaceutical composition (A) comprises telithromycin (I) (0.1-80 wt.%) or its acid addition salts as an active ingredient and a diluting agent (II) (10-50 wt.%) having plastic behavior. - ACTIVITY : Antibacterial. - MECHANISM OF ACTION : None given.